MX2019006233A - Composiciones farmaceuticas y metodos para tratar enfermedades cardiovasculares. - Google Patents
Composiciones farmaceuticas y metodos para tratar enfermedades cardiovasculares.Info
- Publication number
- MX2019006233A MX2019006233A MX2019006233A MX2019006233A MX2019006233A MX 2019006233 A MX2019006233 A MX 2019006233A MX 2019006233 A MX2019006233 A MX 2019006233A MX 2019006233 A MX2019006233 A MX 2019006233A MX 2019006233 A MX2019006233 A MX 2019006233A
- Authority
- MX
- Mexico
- Prior art keywords
- histamine
- receptor agonist
- receptor antagonist
- methods
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 abstract 2
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- 229940105958 Histamine H2 receptor agonist Drugs 0.000 abstract 2
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 abstract 2
- 229940121359 adenosine receptor antagonist Drugs 0.000 abstract 2
- 239000000048 adrenergic agonist Substances 0.000 abstract 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 2
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 abstract 2
- 239000000480 calcium channel blocker Substances 0.000 abstract 2
- 239000003393 histamine H1 receptor agonist Substances 0.000 abstract 2
- 239000003386 histamine H2 receptor agonist Substances 0.000 abstract 2
- 239000003395 histamine H3 receptor antagonist Substances 0.000 abstract 2
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 abstract 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 abstract 2
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 abstract 1
- 229940124241 Histamine H1 receptor agonist Drugs 0.000 abstract 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 abstract 1
- 229960003556 aminophylline Drugs 0.000 abstract 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 abstract 1
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960004536 betahistine Drugs 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229960001340 histamine Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229950008204 levosalbutamol Drugs 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 229960001597 nifedipine Drugs 0.000 abstract 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 229960002052 salbutamol Drugs 0.000 abstract 1
- 229960000278 theophylline Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente solicitud se provee una composición farmacéutica que comprende dos o más compuestos, en la cual cada compuesto es de manera independiente un inhibidor de fosfodiesterasa, un antagonista del receptor de adenosina, un bloqueador del canal de calcio, un agonista del receptor H1 de histamina, un agonista del receptor H2 de histamina, un antagonista del receptor H3 de histamina, o un agonista del receptor adrenérgico ß2. En la presente solicitud también se provee un método para tratar o mejorar una enfermedad cardiovascular en un individuo, que comprende administrar al individuo que lo necesite dos o más compuestos, en el cual cada compuesto es de manera independiente un inhibidor de fosfodiesterasa (teofilina), un antagonista del receptor de adenosina (aminofilina), un bloqueador del canal de calcio (nifedipina), un agonista del receptor H1 de histamina, un agonista del receptor H2 de histamina, un antagonista del receptor H3 de histamina (betahistina o un metabolito de la misma), o un agonista del receptor adrenérgico ß2 (levalbuterol o albuterol), en el cual la composición farmacéutica está formulada en una forma de dosificación para administración inyectable u oral.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762503902P | 2017-05-09 | 2017-05-09 | |
| US201862652812P | 2018-04-04 | 2018-04-04 | |
| PCT/US2018/031505 WO2018208723A1 (en) | 2017-05-09 | 2018-05-08 | Pharmaceutical compositions and methods of treating cardiovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019006233A true MX2019006233A (es) | 2019-08-01 |
| MX386873B MX386873B (es) | 2025-03-19 |
Family
ID=64096944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006233A MX386873B (es) | 2017-05-09 | 2018-05-08 | Composiciones farmacéuticas y usos de las mismas para tratar enfermedades cardiovasculares |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US11266651B2 (es) |
| EP (1) | EP3621593B1 (es) |
| JP (1) | JP6714796B2 (es) |
| KR (1) | KR102197429B1 (es) |
| CN (1) | CN109890366B (es) |
| AR (1) | AR113827A1 (es) |
| AU (1) | AU2018266106B2 (es) |
| BR (1) | BR112019023101B1 (es) |
| CA (1) | CA3038153C (es) |
| CL (1) | CL2019003216A1 (es) |
| CO (1) | CO2019010510A2 (es) |
| IL (1) | IL269901B (es) |
| JO (1) | JOP20190219A1 (es) |
| MX (1) | MX386873B (es) |
| PE (1) | PE20200741A1 (es) |
| PH (1) | PH12019502330A1 (es) |
| RU (1) | RU2715419C1 (es) |
| SG (1) | SG11201902949PA (es) |
| WO (1) | WO2018208723A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11510924B2 (en) | 2017-05-09 | 2022-11-29 | CARDIX Therapeutics, LLC | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases |
| JOP20190219A1 (ar) * | 2017-05-09 | 2019-09-22 | Cardix Therapeutics LLC | تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية |
| US10582716B1 (en) * | 2019-06-14 | 2020-03-10 | Lennham Pharmaceuticals, Inc. | Deuterated caffeine and uses thereof |
| KR102249155B1 (ko) * | 2019-07-26 | 2021-05-07 | 주식회사 코아팜바이오 | 유데나필을 함유하는 약제학적 조성물 |
| JP2024503727A (ja) * | 2021-01-20 | 2024-01-26 | アルト ニューロサイエンス，インコーポレーテッド | うつ病及び関連する状態の治療のための併用薬物戦略としてのｃＡＭＰシグナル伝達の強化 |
| CN112717092A (zh) * | 2021-01-22 | 2021-04-30 | 行艳丽 | 一种预防心脑血管疾病的中药及制备方法 |
| US11452690B1 (en) | 2021-01-27 | 2022-09-27 | ECI Pharmaceuticals, LLC | Oral liquid compositions comprising amlodipine besylate and methods of using the same |
| US12194046B2 (en) | 2021-03-09 | 2025-01-14 | Lennham Pharmaceuticals, Inc. | D9-caffeine compositions and uses thereof |
| US20250051277A1 (en) | 2021-10-29 | 2025-02-13 | Sensorium Therapeutics, Inc. | Delivery of therapeutic alkaloid compounds |
| WO2023076547A1 (en) * | 2021-10-29 | 2023-05-04 | Sensorium Therapeutics, Inc. | Deuterated forms of alkaloid compounds and therapeutic uses thereof |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| CA2224381A1 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| HUP0000116A3 (en) | 1996-10-01 | 2000-08-28 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| CA2219698C (en) | 1996-10-31 | 2007-09-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| KR20000057693A (ko) | 1996-12-20 | 2000-09-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 지효성 제제의 제조 방법 |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| RU2115419C1 (ru) | 1997-07-09 | 1998-07-20 | Геннадий Иванович Марков | Лекарственное средство для адсорбционной терапии воспалительных заболеваний слизистых оболочек |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| WO2000000184A2 (en) | 1998-06-26 | 2000-01-06 | Delack Elaine A | Use of histamine h2 mimicking substances for the treatment of multiple sclerosis |
| US7001609B1 (en) | 1998-10-02 | 2006-02-21 | Regents Of The University Of Minnesota | Mucosal originated drug delivery systems and animal applications |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| HU229439B1 (hu) | 1999-08-21 | 2013-12-30 | Takeda Gmbh | Roflumilast és salmeterol szinergetikus kombinációja |
| AU2001276608A1 (en) | 2000-08-30 | 2002-03-13 | Pfizer Products Inc. | Sustained release formulations for growth hormone secretagogues |
| US7025992B2 (en) | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
| US10004684B2 (en) | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
| GB2381450B (en) | 2001-10-31 | 2006-05-31 | Gw Pharma Ltd | Compositions for administration of natural or synthetic cannabinoids by vaporisation |
| EP1691789B1 (en) | 2003-11-25 | 2017-12-20 | SmithKline Beecham (Cork) Limited | Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
| EP1848424B1 (en) * | 2005-01-31 | 2017-04-05 | Mylan Laboratories, Inc | Pharmaceutical composition comprising hydroxylated nebivolol |
| FR2886150B1 (fr) | 2005-05-24 | 2007-08-24 | Flamel Technologies Sa | Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique |
| US8207188B2 (en) * | 2006-04-07 | 2012-06-26 | Michalis Nicolaou | Treatment of diseases modulated by a H4 receptor agonist |
| WO2008019106A1 (en) | 2006-08-04 | 2008-02-14 | Artesian Therapeutics, Inc. | Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor |
| EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
| US20100086483A1 (en) * | 2008-09-29 | 2010-04-08 | Gilead Palo Alto, Inc. | Method of multidetector computed tomagraphy |
| GB201113662D0 (en) | 2011-08-08 | 2011-09-21 | Prosonix Ltd | Pharmaceutical compositions |
| CN102631320B (zh) * | 2012-04-24 | 2014-04-02 | 吉林大学珠海学院 | 一种盐酸倍他司汀脂质体及其制备方法 |
| US11026925B2 (en) | 2016-01-20 | 2021-06-08 | Shenzhen Salubris Pharmaceuticals Co. Ltd. | Angiotensin II receptor antagonist metabolite and NEP inhibitor composite and preparation method thereof |
| EP3231417B1 (de) | 2016-04-15 | 2018-12-05 | Dr. Gerhard Mann Chem.-Pharm. Fabrik GmbH | Lagerungsstabile, ophthalmische zusammensetzung |
| JOP20190219A1 (ar) * | 2017-05-09 | 2019-09-22 | Cardix Therapeutics LLC | تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية |
-
2017
- 2017-06-16 JO JOP/2019/0219A patent/JOP20190219A1/ar unknown
-
2018
- 2018-05-07 US US15/973,132 patent/US11266651B2/en active Active
- 2018-05-08 MX MX2019006233A patent/MX386873B/es unknown
- 2018-05-08 SG SG11201902949PA patent/SG11201902949PA/en unknown
- 2018-05-08 PE PE2019002140A patent/PE20200741A1/es unknown
- 2018-05-08 RU RU2019110247A patent/RU2715419C1/ru active
- 2018-05-08 WO PCT/US2018/031505 patent/WO2018208723A1/en not_active Ceased
- 2018-05-08 CN CN201880003608.6A patent/CN109890366B/zh active Active
- 2018-05-08 BR BR112019023101-3A patent/BR112019023101B1/pt not_active IP Right Cessation
- 2018-05-08 KR KR1020197014692A patent/KR102197429B1/ko active Active
- 2018-05-08 AU AU2018266106A patent/AU2018266106B2/en active Active
- 2018-05-08 CA CA3038153A patent/CA3038153C/en active Active
- 2018-05-08 JP JP2019515882A patent/JP6714796B2/ja active Active
- 2018-05-08 EP EP18798353.1A patent/EP3621593B1/en active Active
- 2018-11-05 AR ARP180103206A patent/AR113827A1/es not_active Application Discontinuation
-
2019
- 2019-03-14 US US16/353,675 patent/US10758544B2/en active Active
- 2019-10-07 IL IL269901A patent/IL269901B/en active IP Right Grant
- 2019-10-11 PH PH12019502330A patent/PH12019502330A1/en unknown
- 2019-11-08 CL CL2019003216A patent/CL2019003216A1/es unknown
- 2019-12-09 CO CONC2019/0010510A patent/CO2019010510A2/es unknown
-
2020
- 2020-08-31 US US17/008,538 patent/US11491159B2/en active Active
-
2022
- 2022-03-08 US US17/689,576 patent/US11878017B2/en active Active
- 2022-11-08 US US18/053,478 patent/US11911389B2/en active Active
-
2024
- 2024-01-23 US US18/420,659 patent/US12472186B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019010510A2 (es) | Composiciones farmacéuticas y métodos para tratar enfermedades cardiovasculares | |
| MX2024004332A (es) | Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos. | |
| MX384022B (es) | Tetrahidropiranil amino-pirrolopirimidinona y metodos de uso de la misma. | |
| ZA202007679B (en) | Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and sglt-2 inhibitor and preparation methods and uses thereof | |
| JOP20200001A1 (ar) | كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم | |
| CL2019001265A1 (es) | Variantes de il-2 para el tratamiento de enfermedades autoinmunes. | |
| CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
| BR112017004448A2 (pt) | uso de agente de reforço de receptor gabaa na preparação de medicamento sedativo e anestésico | |
| CY1124243T1 (el) | Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1 | |
| UY37028A (es) | Compuestos inhibidores de prostaglandina d sintasa ematopoyética (h-pgds | |
| MX2017010477A (es) | Compuestos triciclicos y usos de los mismos en medicina. | |
| MA44238A (fr) | Procédés d'augmentation de l'efficacité d'un vaccin par administration d'un antagoniste d'il-4r | |
| EA201792066A1 (ru) | Оптимизированная комбинированная терапия и ее применение для лечения злокачественной опухоли и аутоиммунного заболевания | |
| MX2019002265A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| BR112019003811A2 (pt) | composição farmacêutica, método para aumentar os níveis plasmáticos de antagonista do receptor de nmda em um sujeito que precisa do mesmo, método para tratar uma doença ou transtorno em um sujeito que precisa do mesmo e uso da composição | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| EA033530B1 (ru) | Композиции 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида | |
| MX390461B (es) | Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion | |
| TW201613577A (en) | Pharmaceutical combinations | |
| EA201891578A1 (ru) | Композиции 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил-2,2-дифторацетамида | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| PE20181296A1 (es) | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para el tratamiento de la enfermedad de parkinson | |
| MX2019007163A (es) | Sales cristalinas y polimorfos de un antagonista de p2x3. | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| BR112020010149A8 (pt) | Derivado de pirimidina sulfamida e método de preparação e aplicação médica |